Celcuity Inc. (NASDAQ:CELC) Holdings Raised by Barclays PLC

Barclays PLC lifted its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 567.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 53,605 shares of the company’s stock after purchasing an additional 45,576 shares during the quarter. Barclays PLC owned about 0.14% of Celcuity worth $800,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. BNP Paribas Financial Markets raised its position in Celcuity by 2,083.4% in the third quarter. BNP Paribas Financial Markets now owns 45,110 shares of the company’s stock worth $673,000 after acquiring an additional 43,044 shares in the last quarter. Samlyn Capital LLC raised its position in Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock worth $21,735,000 after acquiring an additional 637,190 shares in the last quarter. Driehaus Capital Management LLC raised its position in Celcuity by 62.3% in the second quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock worth $3,351,000 after acquiring an additional 78,525 shares in the last quarter. Geode Capital Management LLC raised its position in Celcuity by 27.6% in the third quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after acquiring an additional 136,518 shares in the last quarter. Finally, Blue Owl Capital Holdings LP bought a new stake in Celcuity in the second quarter worth about $1,065,000. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

CELC has been the topic of a number of analyst reports. Stifel Nicolaus lifted their price target on Celcuity from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research note on Friday, November 15th. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $29.17.

Celcuity Stock Up 6.6 %

Shares of CELC stock opened at $11.23 on Thursday. The firm has a market cap of $416.97 million, a PE ratio of -4.30 and a beta of 0.74. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65. Celcuity Inc. has a 12 month low of $10.35 and a 12 month high of $22.19. The stock has a 50 day moving average of $12.97 and a 200-day moving average of $15.05.

Celcuity Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.